Free Trial
NASDAQ:ELVN

Enliven Therapeutics Q4 2024 Earnings Report

Enliven Therapeutics logo
$20.51 +0.66 (+3.32%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$20.50 -0.02 (-0.07%)
As of 05/2/2025 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Enliven Therapeutics Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enliven Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Enliven Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Friday, May 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Enliven Therapeutics Earnings Headlines

Enliven Therapeutics: Awaiting Additional Trial Data
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
TD Cowen Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
See More Enliven Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email.

About Enliven Therapeutics

Enliven Therapeutics (NASDAQ:ELVN), a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

View Enliven Therapeutics Profile

More Earnings Resources from MarketBeat